BioSpace News Archive

In a phase 1 study, RBT-6 was administered to study participants with moderate to severe chronic kidney disease (CKD) and showed an increase in expression of antioxidant proteins. These findings may help develop a pharmacologic stress test for determining antioxidant reserves in CKD and other medical conditions.

Today, Abbott (NYSE: ABT) announced results from multiple new real-world studies1,2,3,4 that demonstrate how use of the FreeStyle Libre system, the world-leading5 continuous glucose monitoring (CGM) technology, can lead to significant clinical benefits among people living with type 1 and type 2 diabetes

KRS Global Biotechnology, Inc., a market-leading registered and inspected 503B Human Outsourcing Facility, is under new ownership and management as of Q1 2020. Cleveland Diabetes Care, Inc. (CDC), a clinical-stage biopharmaceutical,

Tyto Care names Sellers as VP Marketing to lead the company’s brand strategy in B2B and B2C efforts and Eitan as CFO to help expand business operations globally as demand for the unique telehealth solution surges

RapidAI, the worldwide leader in advanced imaging for stroke, today announced the launch of RapidAI Insights. A unique new analytics platform, RapidAI Insights presents Rapid® scan, treatment, and outcomes data to help hospitals and systems make more-informed business decisions, reduce costs across

Healthcare Integrated Technologies, Inc. (“HITC”) is pleased to announce the addition of Ken Greenwood as our Chief Technology Officer.

Today Proximo Medical , LLC, a business acceleration solution that addresses medical device commercialization challenges among startup and established medical device technologies looking to expand adoption in the U.S., announced a partnership with Coala Life , a leading Swedish-headquartered digital health company, in select U.S.

ISOThrive Inc., a microbiome therapeutics company announced today that the U.S. Patent and Trademark Office has issued a Composition of Matter patent for its proprietary microbiome therapeutic Maltosyl-Isomaltooligosaccharide (MIMO™). The company has c

Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that it has developed a proprietary bispecific antibody technology platform, PACbodyTM

International, multi-center, randomized, double-blind, placebo-controlled clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in patients infected with COVID-19 Novel Mechanism of Action - a selective dipeptidase-1 antagonist that prevents leukocyte adhesion to endothelial cells reducing inflammation and subsequent organ damage Study also recently approved by Health Canada TORONTO, June 16, 2020 (GLOBE NEWSWIRE) --